Phase 2-3 Clinical Trial Services
Clinilabs Drug Development Corporation, the only global, full-service contract research organization (CRO) focused exclusively on central nervous system (CNS) drug development, offers a full range of high quality, timely and cost-effective phase 2-3 clinical drug development services to help our customers speed new CNS medications to market. We are experts in and committed to the development of CNS medicines that treat a range of psychiatric, neurological and substance abuse disorders, including mental health disorders, Alzheimer’s disease, migraine headache and opioid use disorders in addition to rare diseases in the CNS category.
Clinilabs has global capabilities and conducts phase 2-3 clinical trials in Asia, through Clinilabs Asia Pacific, and Europe.
Clinilabs has conducted more than 675 CNS clinical trials in our 20-year history and has played a pivotal role in the approval of 19 new therapies across 10 CNS indications. We are a patient-centric partner who shares your goal of speeding new CNS medicines to market to transform patients’ lives.
The reward for work well done is the opportunity to do more.
– Jonas Salk
We empower study participants through informed decisions regarding study participation.
Clinilabs offers a full range of Phase I, II and III clinical development services.